Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
51.53
+0.02 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
45
46
Next >
(GSK) - Analyzing GSK's Short Interest
↗
July 07, 2023
Via
Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
↗
July 07, 2023
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...
Via
Benzinga
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
↗
July 05, 2023
Raymond James has initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a price target of $9 and
Via
Benzinga
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit
↗
July 05, 2023
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.
Via
Benzinga
Moderna Initiates Regulatory Application Process Seeking Approval For Its RSV Vaccine In Older Adults
↗
July 05, 2023
Moderna Inc (NASDAQ: MRNA) provided an update on regulatory submissions for the mRNA-1345 vaccine to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease in
Via
Benzinga
Better Artificial Intelligence Stock: GSK or Eli Lilly?
↗
June 28, 2023
Which of these AI-powered drugmakers is the better buy right now?
Via
The Motley Fool
Is GSK a Strong Buy Right Now?
↗
June 26, 2023
The drugmaker ought to appeal to value and income investors.
Via
The Motley Fool
2 Stocks Defying Friday's Market Downturn
↗
June 23, 2023
Stock markets opened lower as Wall Street took a pause from the bull run.
Via
The Motley Fool
Haleon Contemplates Sale of Non-Core Businesses, Including Nicotinell Brand: A Strategy Shift Towards Core Products
↗
July 05, 2023
Haleon Plc (NYSE: HLN), a consumer health company, is reportedly considering divesting some smoking cessation products as part of a strategy to sell non-core businesses.
Via
Benzinga
First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California
↗
July 03, 2023
The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs.
Via
Benzinga
Drugmaker GSK: Becoming a Healthier Value Stock
June 27, 2023
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.
Via
MarketBeat
Topics
Lawsuit
Baidu Says Ernie Bot Beats ChatGPT, Meta's WhatsApp Business Soars Past 200M Users, Walgreens Earnings Disappointment: Today's Top Stories
↗
June 27, 2023
CNBC ChatGPT Vs. Baidu's Ernie Bot - Chinese Tech Giant Says Ernie Beat ChatGPT
Via
Benzinga
Second Most Prevalent Bacterial Sexually Transmitted Infection: GSK's Gonorrhea Vaccine Secures FDA Track
↗
June 27, 2023
The FDA has granted Fast Track designation to GSK plc's (NYSE:
Via
Benzinga
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
↗
June 26, 2023
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other...
Via
Benzinga
Why Shares of CureVac Jumped This Week
↗
June 23, 2023
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
Via
The Motley Fool
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 23, 2023
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.
Via
Benzinga
GSK Surges After Settling First Zantac Case, But A 'Conveyor Belt' Of Claims Looms
↗
June 23, 2023
GSK settled with James Goetz for an undisclosed amount of money. But thousands of cases remain.
Via
Investor's Business Daily
Crypto Analyst Says Bitcoin Can Break $32K Level, Nikola Moves Forward With Test Road Trips Despite Weak Demand & Internal Conflict, Retailers' Subscriptions Under FTC Scrutiny: Today's Top Stories
↗
June 23, 2023
Benzinga
Via
Benzinga
GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month
↗
June 23, 2023
GSK plc (NYSE: GSK) has reached a confidential settlement with James Goet
Via
Benzinga
Trupanion, IonQ, 3M And Other Big Stocks Moving Higher In Friday's Pre-Market Session
↗
June 23, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Intel Voices Plans To Restructure Manufacturing Business, Bumble's BFF App, Spirit AeroSystems To Stop Work At Kansas Plant Amid Workers Strike: Today's Top Stories
↗
June 22, 2023
Reuters
Via
Benzinga
RSV Vaccines from Pfizer and GSK Gain CDC Advisory Committee's Favor for Older Adults
↗
June 22, 2023
The US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines from Pfizer Inc (NYSE: PFE) and GSK...
Via
Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
↗
June 21, 2023
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy.
Via
InvestorPlace
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
June 21, 2023
From
GSK plc
Via
Business Wire
Pfizer's Elderly Vaccine Efficacy Drops Slightly After 18 Months, New Clinical Trials Reveal - CDC Advisory Panel Set To Vote Today On Recommended Use Of RSV Shots
↗
June 21, 2023
Pfizer Inc's (NYSE: PFE) vaccine for elderly 60 and above was slightly less effective after 18 months, according to the company's clinical trial
Via
Benzinga
GSK's Recently Approved Vaccine Offers Long-Term Protection Against RSV in Older Adults, New Data Reveals
↗
June 21, 2023
GSK plc (NYSE: GSK) announced
Via
Benzinga
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
June 21, 2023
From
GSK plc
Via
Business Wire
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
June 20, 2023
From
GSK plc
Via
Business Wire
Sanofi Stock Is Trading Higher Today - Here's Why
↗
June 20, 2023
Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to...
Via
Benzinga
3 Undervalued Consumer Stocks to Buy in June
↗
June 20, 2023
These undervalued consumer stocks to buy could attract investor attention as possible hedges against inflation and a recession.
Via
InvestorPlace
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
45
46
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.